Ruth O’Regan

15.7k total citations · 2 hit papers
162 papers, 6.9k citations indexed

About

Ruth O’Regan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ruth O’Regan has authored 162 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 61 papers in Cancer Research and 57 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ruth O’Regan's work include Advanced Breast Cancer Therapies (51 papers), Breast Cancer Treatment Studies (50 papers) and HER2/EGFR in Cancer Research (43 papers). Ruth O’Regan is often cited by papers focused on Advanced Breast Cancer Therapies (51 papers), Breast Cancer Treatment Studies (50 papers) and HER2/EGFR in Cancer Research (43 papers). Ruth O’Regan collaborates with scholars based in United States, France and China. Ruth O’Regan's co-authors include Elisavet Paplomata, Shuming Nie, Maksym Yezhelyev, Xiaohu Gao, Rita Nahta, Zahi Mitri, V. Craig Jordan, Yun Xing, Jonathan W. Simons and Victoria L. Seewaldt and has published in prestigious journals such as The Lancet, Journal of the American Chemical Society and Advanced Materials.

In The Last Decade

Ruth O’Regan

155 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

2014 452 citations Elisavet Paplomata, Ruth O’Regan profile →
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

2012 387 citations Ruth O’Regan et al. profile →

Peers

Countries citing papers authored by Ruth O’Regan

Since Specialization

Citations

This map shows the geographic impact of Ruth O’Regan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth O’Regan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth O’Regan more than expected).

Fields of papers citing papers by Ruth O’Regan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth O’Regan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth O’Regan. The network helps show where Ruth O’Regan may publish in the future.

Co-authorship network of co-authors of Ruth O’Regan

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth O’Regan. A scholar is included among the top collaborators of Ruth O’Regan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth O’Regan. Ruth O’Regan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer 2023 ·Breast Cancer Research and Treatment ·Caitlin Taylor, Jane Meisel, Aimee J. Foreman, Christy Russell, Dipankar Bandyopadhyay, (unknown), (unknown), Amelia Zelnak, Harry D. Bear, Ruth O’Regan	5
2	A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm 2023 ·Cancer ·Arya Mariam Roy, (unknown), (unknown), Ruth O’Regan, Shipra Gandhi	10
3	When the personal becomes political: The impact of the Dobbs decision on women with cancer 2022 ·Cancer ·Jane Meisel, (unknown), (unknown), Wendy Vitek, Ruth O’Regan	1
4	Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study 2021 ·Clinical Cancer Research ·Sara M. Tolaney, Kevin Kalinsky, Virginia Kaklamani, David R. D’Adamo, Gursel Aktan, Michaela L. Tsai, Ruth O’Regan, Peter A. Kaufman, Sharon Wilks, Eleni Andreopoulou, Debra A. Patt, Yuan Yuan, Grace Wang, (unknown), Dongyuan Xing, (unknown), Vassiliki Karantza, Sami Diab	90
5	Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy 2021 ·Nature Cancer ·Jason I. Griffiths, Jinfeng Chen, Patrick A. Cosgrove, Anne O’Dea, Priyanka Sharma, X. Cynthia, Meghna S. Trivedi, Kevin Kalinsky, Kari B. Wisinski, Ruth O’Regan, Issam Makhoul, Laura M. Spring, Aditya Bardia, Frederick R. Adler, Adam L. Cohen, Jeffrey T. Chang, Qamar J. Khan, Andrea H. Bild	41
6	Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling 2019 ·Cancers ·Iram Fatima, (unknown), (unknown), Jackelyn A. Alva-Ornelas, Aysha B. Khalid, (unknown), Peter Wend, (unknown), (unknown), Raisa I. Krutilina, Daniel L. Johnson, Ruth O’Regan, Victoria L. Seewaldt, Tiffany N. Seagroves, Susan A. Krum, Gustavo A. Miranda‐Carboni	27
7	Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer 2019 ·Clinical Breast Cancer ·Jane Meisel, Jing Zhao, Aili Suo, Chao Zhang, Zhimin Wei, Caitlin Taylor, Ritu Aneja, Uma Krishnamurti, Zaibo Li, Rita Nahta, Ruth O’Regan, Xiaoxian Li	30
8	Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer 2018 ·Journal of the National Comprehensive Cancer Network ·Ruth O’Regan, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
9	Molecular Homology and Difference between Spontaneous Canine Mammary Cancer and Human Breast Cancer 2014 ·Cancer Research ·Deli Liu, Huan Xiong, Angela E. Ellis, Nicole C. Northrup, Carlos O. Rodriguez, Ruth O’Regan, Stephen Dalton, Shaying Zhao	101
10	Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach? 2014 ·Cancer ·Elisavet Paplomata, Rita Nahta, Ruth O’Regan	15
11	Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers 2012 ·Breast Cancer Research and Treatment ·Rita Nahta, Ruth O’Regan	67
12	Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells 2011 ·Molecular Cancer Therapeutics ·Tongrui Liu, Rami Yacoub, LaTonia Taliaferro‐Smith, Shi‐Yong Sun, Tisheeka Graham, Ryan S. Dolan, (unknown), Mourad Tighiouart, Lily Yang, Amy L. Adams, Ruth O’Regan	88
13	The Negative Effect of Triple-Negative Breast Cancer on Outcome after Breast-Conserving Therapy 2011 ·Annals of Surgical Oncology ·Sandra S. Zaky, (unknown), (unknown), Karen D. Godette, Jonathan J. Beitler, (unknown), Ruth O’Regan, Esther S. Yu, David S. Yu, Jerome C. Landry	41
14	Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab 2010 ·Journal of Clinical Oncology ·Fabrice André, Mario Campone, Ruth O’Regan, C. Manlius, Cristian Massacesi, (unknown), Pabak Mukhopadhyay, Jean‐Charles Soria, Michael Naughton, Sara A. Hurvitz	148
15	Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes 2010 ·Cancer ·Mary Jo Lund, Eboneé N. Butler, Brionna Y. Hair, Kevin C. Ward, (unknown), (unknown), A. Rana Bayakly, Ruth O’Regan, Paula M. Vertino, J. William Eley	89
16	In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells 2009 ·Cancer Chemotherapy and Pharmacology ·Tuba Ozbay, Donald L. Durden, Tongrui Liu, Ruth O’Regan, Rita Nahta	36
17	Bidirectional Crosstalk between Leptin and Insulin-like Growth Factor-I Signaling Promotes Invasion and Migration of Breast Cancer Cells via Transactivation of Epidermal Growth Factor Receptor 2008 ·Cancer Research ·Neeraj K. Saxena, (unknown), Brandi B. Knight, Didier Merlin, Frank A. Anania, Ruth O’Regan, Dipali Sharma	176
18	Simultaneous, quantitative detection of multiple biomarkers in breast cancers using semiconductor multicolor quantum dots 2006 ·Cancer Research ·(unknown), (unknown), Tongrui Liu, Caroline Morris, Xiaohu Gao, Shuming Nie, Ruth O’Regan	4
19	Multiplex molecular profiling of breast cancer cell lines with quantum dot-antibody conjugates 2005 ·Cancer Research ·Maksym Yezhelyev, Caroline Morris, Xiaohu Gao, Shuming Nie, Melinda M. Lewis, C. M. S. Cohen, Ruth O’Regan	2
20	Chemoprevention of Breast Cancer 2001 ·Cancer treatment and research ·Ruth O’Regan, V. Craig Jordan	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact